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Although the regulation of developmental and 
inflammatory angiogenesis is well characterized, 
the study of lymphangiogenesis is still in its 
infancy despite the multitude of critical roles 
performed  by  the  lymphatic  vasculature.  The 
primary function of the lymphatic vascular sys-
tem is to drain fluid from the extracellular matrix 
(Oliver, 2004; Cueni and Detmar, 2008). In ad-
dition to maintaining low tissue pressure, this 
action also serves to deliver antigen and cyto-
kines from sites of inflammation to draining 
lymph nodes (Oliver, 2004; Cueni and Detmar, 
2008). Lymphatic capillaries are the primary 
route for the transport of antigen-loaded APCs 
to draining lymph nodes (von Andrian and 
Mempel, 2003), and tissues devoid of lymphatic 
vasculature, such as the cornea and brain, are 
characterized by immune privilege (Streilein, 
2003; Cursiefen, 2007; Galea et al., 2007; Lambe 
et al., 2007). Lymphatic drainage is crucial to the 
development of immunity but, conversely, can 
contribute to destructive inflammation during 
graft rejection, autoimmunity, and chronic in-
fection (Paavonen et al., 2002; Kerjaschki et al., 
2004; Baluk et al., 2005; Fricke et al., 2007).
As a result, considerable investment has been 
made to clarify the mechanisms of inflammatory 
lymphangiogenesis, the growth of lymphatic 
vessels from preexisting vasculature. Studies of 
chronic  inflammation  during  graft  rejection, 
bacterial infection, and after administration of 
inflammatory cytokines, such as fibroblast growth 
factor b and IL-1, have suggested common lym-
phangiogenic mechanisms between these models. 
The initiation of lymphangiogenesis is charac-
terized by the recruitment of activated macro-
phages to a site of inflammation and subsequent 
production of the prolymphangiogenic cytokines 
vascular endothelial growth factor (VEGF) C 
or D (Cursiefen et al., 2003, 2004b; Watari et al., 
2008; Kataru et al., 2009). Ligation of the lym-
phatic vessel endothelial cell expressed receptor, 
VEGF receptor (VEGFR) 3, by these cytokines 
induces mitosis and lymphatic vessel branching 
toward their source (Podgrabinska et al., 2002; 
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Inflammatory lymphangiogenesis plays a crucial role in the development of inflammation 
and transplant rejection. The mechanisms of inflammatory lymphangiogenesis during bacte-
rial infection, toll-like receptor ligand administration, and wound healing are well charac-
terized and depend on ligands for the vascular endothelial grow factor receptor (VEGFR) 3 
that are produced by infiltrating macrophages. But inflammatory lymphangiogenesis in 
nonlymphoid tissues during chronic viral infection is unstudied. Herpes simplex virus 1 
(HSV-1) infection of the cornea is a leading cause of blindness and depends on aberrant 
host immune responses to antigen within the normally immunologically privileged cornea. 
We report that corneal HSV-1 infection drives lymphangiogenesis and that corneal lym-
phatics persist past the resolution of infection. The mechanism of HSV-1–induced lym-
phangiogenesis was distinct from the described mechanisms of inflammatory 
lymphangiogenesis. HSV-1–elicited lymphangiogenesis was strictly dependent on VEGF-A/
VEGFR-2 signaling but not on VEGFR-3 ligands. Macrophages played no role in the induc-
tion of lymphangiogenesis and were not a detectable source of VEGF-A. Rather, using 
VEGF-A reporter transgenic mice, we have identified infected epithelial cells as the primary 
source of VEGF-A during HSV-1 infection. Our results indicate that HSV-1 directly induces 
vascularization of the cornea through up-regulation of VEGF-A expression.
© 2010 Wuest et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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HSV-1–infected corneal epithelial cells. Our results indicate 
that HSV-1 directly influences the vascular environment of 
the cornea through VEGF-A expression. HSV-1 induces in-
flammatory lymphangiogenesis in the cornea by a mechanism 
distinct from previously described models of inflammatory 
lymphangiogenesis and is not simply an innate response to viral 
infection, as infection with vesicular stomatitis virus (VSV) did 
not up-regulate expression of VEGF-A in infected cells.
RESULTS
HSV-1 infection induces corneal lymphangiogenesis
Although the normal cornea is devoid of blood and lym-
phatic vessels, it is surrounded by rings of both vessel types in 
the region proximal to the cornea, the limbus. To determine 
if HSV-1 infection induced sprouting of limbal lymphatics 
into the cornea, C57BL/6 mice were infected with 105 PFU 
HSV-1 and corneas were harvested at 1, 3, 5, and 7 d post 
infection (PI). Confocal microscopic examination of corneas 
for the lymphatic vessel-specific antigen LYVE-1 indicated 
that HSV-1 induced rapid sprouting of limbal lymphatics. Small 
sprouts were observed as early as day 1 PI (Fig. 1). Sprouts 
continued extension into the cornea through day 7 PI, which 
was the last time point analyzed using 105 PFU HSV-1 because 
of animal mortality. In contrast, mock-infected animals, which 
were scarified but received PBS rather than an inoculum of 
HSV-1, did not show infiltration of lymphatic vessels into the 
cornea (Fig. 1, bottom right). Thus, HSV-1 infection elicited 
corneal lymphangiogenesis.
Inflammatory lymphangiogenesis during HSV-1 infection  
is comparable to angiogenesis, and corneal lymphatics exist 
beyond resolution of infection
Angiogenesis is a well recognized complication of HSK that is 
believed to contribute to both corneal opacity and the in-
creased risk of corneal transplant rejection observed in HSK-
affected patients. However, corneal lymphangiogenesis is 
believed to be at least as significant in graft rejection as angio-
genesis. As HSV-1–induced lymphangiogenesis has previously 
not been described, we sought to compare the relative rates of 
blood and lymphatic vessel extension into the cornea after 
corneal HSV-1 infection. Blood vessels exhibit high expres-
sion of CD31 with no LYVE-1 expression, whereas lymphatic 
vessels express high levels of LYVE-1 and low or no CD31. 
Corneas were harvested at 1, 3, 5, and 7 d PI from C57BL/6 
mice and examined for expression of LYVE-1 and CD31. 
Harvested corneas included both limbal and corneal tissue as 
the delineation between corneal and limbal tissue. In addition, 
the preexisting ring of limbal lymphatic vessels provided con-
venient and consistent reference points for ensuring equiva-
lent orientation of scans between different corneas. By day 7 
PI, blood and lymphatic vessels showed comparable exten-
sion into the cornea (Fig. 2 A). However, the kinetics of 
growth between the two vessel types differed. Quantitative 
analysis of percentage areas positive for LYVE-1 and CD31HI 
expression in random 100× fields indicated that lymphangio-
genesis preceded angiogenesis. Lymphangiogenesis was observed 
Hong et al., 2004b; Oliver, 2004). Blockade of this pathway, 
either through inhibition of VEGF-C/D/VEGFR-3 signaling 
or depletion of macrophages, profoundly inhibits inflammatory 
lymphangiogenesis (Cursiefen et al., 2004b; Cueni and Detmar, 
2008; Kataru et al., 2009). In vitro and overexpression studies 
also indicate that the related cytokine VEGF-A is capable of 
directly inducing lymphangiogenesis through ligation of the 
receptor VEGFR-2 (Cueni and Detmar, 2008). However, in 
vivo the lymphangiogenic effects of VEGF-A are believed to 
be secondary to the more potent prolymphangiogenic cyto-
kines VEGF-C and -D during inflammatory lymphangiogenesis 
outside of nonlymphoid tissues (Cursiefen et al., 2004b; 
Cueni and Detmar, 2008). However, no studies focused on 
lymphangiogenesis during chronic viral infection have been 
published and the extent to which known mechanisms of 
inflammatory lymphangiogenesis apply during this context 
is unknown.
Herpes simplex virus 1 (HSV-1) is among the most prev-
alent human infections with worldwide seroprevalence rates 
ranging from 50 to 90% (Smith and Robinson, 2002). Infec-
tion is lifelong and characterized by frequent reactivation of 
latent virus within the trigeminal nerve. Newly created virions 
travel down the sensory fibers of the trigeminal nerve, usually 
resulting in the development of orolabial lesions. However, 
the trigeminal nerve also provides sensory fibers to the cornea. 
Thus, reactivation from latency occasionally results in the 
transport of virions to the cornea, resulting in recurring bouts 
of inflammatory keratitis. Herpes simplex keratitis (HSK) is 
among the most severe consequences of HSV-1 infection and 
is believed to be the leading cause of corneal blindness in the 
developed world (Liesegang et al., 1989) as a result of blinding 
corneal opacity elicited by the episodic inflammatory response 
(Carr et al., 2001; Wickham and Carr, 2004; Kaye and 
Choudhary, 2006). The potentially blinding complications 
associated with HSK require viral replication within the cor-
nea. However, HSK is believed to be a product of chronic 
inflammation mediated by the host immune response because 
CD4+ T cells are required for the induction of HSK, as are 
intact lymph nodes draining the sclera and cornea (Carr et al., 
2001; Wickham and Carr, 2004; Biswas et al., 2006).
The extension of blood vessels from surrounding tissues 
into the cornea is a common complication during HSK and 
contributes to inflammation as well as direct impairment of 
vision (Carr et al., 2001; Kaye and Choudhary, 2006; Biswas 
et al., 2006). However, our group has found that in addition 
to inducing corneal hemangiogenesis, ocular HSV-1 infection 
induces the extension of lymphatic vessels into the cornea. In 
sharp contrast to inflammatory lymphangiogenesis during 
chronic bacterial infections, we report that HSV-1–induced 
lymphangiogenesis is not dependent on macrophage recruit-
ment or on the expression of the cytokines VEGF-C or D. 
Rather, lymphangiogenesis was exquisitely dependent on up-
regulated expression of VEGF-A, a cytokine which is typi-
cally associated with angiogenesis. Intriguingly, the source of 
VEGF-A during corneal HSV-1 infection was not an infiltrat-
ing leukocyte population but was instead determined to be JEM VOL. 207, January 18, 2010 
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increase  in  LYVE-1+  percentage  area  between  uninfected 
versus corneas harvested at day 5 PI (Fig. 2 C, uninfected 
0.45 ± 0.07% vs. day 5 PI 3.73 ± 0.57% LYVE-1+ area). This 
increase was not significantly different from that observed be-
tween uninfected corneas versus corneas harvested at day 5 
PI with limbal tissue containing preexisting limbal lymphatics 
(Fig. 2 B, increase in percentage of LYVE-1+ area from day 0 
to day 5 was 2.99 ± 0.66%). As far as could be determined 
within the limitations of our experimental design, the bulk of 
the increase in corneal LYVE-1+ area after HSV-1 occurred 
in the cornea proper. Thus, the increase in LYVE-1+ area was 
unlikely to be the result of either limbal lymphatic vessel dila-
tion or remodeling of limbal lymphatics into the cornea.
HSV-1 disease in humans is characterized by recurring 
cycles of active viral replication followed by latency. During 
latent infection, virus is not detectable in the cornea and in-
flammatory cytokine levels are comparable to those observed in 
normal corneas (He et al., 1999; Carr et al., 2009). Although 
mature blood and lymphatic vessels do not require continuous 
cytokine stimulation for maintenance, immature vessels un-
dergo destruction after withdrawal of angiogenic or lymphan-
giogenic stimuli (Jain, 2003; Karpanen and Alitalo, 2008). 
Corneas were harvested from animals latently infected with 
103 PFU HSV-1 30 d earlier. A lower inoculum of 103 PFU 
HSV-1 rather than 105 PFU was used for this portion of the 
study because of excessive animal mortality using the higher 
dose. By day 30 PI, corneal LYVE-1+ percentage area had in-
creased from 1.85 ± 0.22% in uninfected corneas to 22.6 ± 
2.75% (Fig. 2 D). As with blood vessels, lymphatic vessels re-
mained after resolution of viral replication (Fig. 2 E), which 
typically occurs between days 7 and 14 PI depending on in-
oculum and viral strain. LYVE-1+ vessels exhibited compara-
ble extension past the limbus into the cornea as CD31HI blood 
vessels. Because of exceedingly high animal mortality, it is un-
clear whether active lymphangiogenesis is still occurring by 
day 30 PI or whether the presence of corneal blood and lym-
phatic vessels is the result of persistence past resolution of an-
giogenic or lymphangiogenic stimulation. However, it is clear 
that HSV-1–induced corneal lymphatics remained after reso-
lution of detectable viral replication. Furthermore, HSV-1–
induced lymphatic vessels were capable of draining soluble 
fluorescently labeled dextran from the cornea to the draining 
lymph nodes and this capability remained at day 30 PI, indi-
cating functionality (Fig. S2). This is in contrast to uninfected 
eyes in which the placement of soluble fluorescently labeled 
dextran was not apparent in the draining lymph node after 
placement in the cornea (Fig. S2).
HSV-1–induced lymphangiogenesis is dependent on VEGF-
A/VEGFR-2 but not VEGF-C/D/VEGFR-3
Corneal HSV-1–induced lymphatics express the VEGF family 
receptors VEGFR-2 and VEGFR-3 (Fig. 3, A and B; isotypic 
controls shown in Fig. S1), which bind the prolymphangio-
genic cytokines VEGF-A/C/D or VEGF-C/D, respectively. 
To test dependence on these ligands, we administered com-
petitive inhibitors composed of the extracellular domains of 
as early as day 1 PI with rapid increases in LYVE-1+ percent-
age areas through day 5 PI (Fig. 2 B). In contrast, angiogenesis 
was delayed, with no detectable increase in CD31HI percent-
age area until day 5 PI, after which angiogenesis appeared to 
occur more rapidly than lymphangiogenesis (Fig. 2 B).
As quantified scans included both limbal and corneal tissue, 
the increases in total LYVE-1+ and CD31+ areas could not be 
simply the result of remodeling of existing limbal lymphatics 
into the cornea proper, as total LYVE-1+ and CD31+ area 
would be unchanged in this case. Examination of corneas 
harvested without limbal tissue showed an 3.28 ± 0.64% 
Figure 1.  HSV-1 infection induces lymphangiogenesis. WT mice 
were scarified and then either saline (mock) or 105 PFU HSV-1 was applied 
to the cornea. The corneas were harvested at the indicated day PI and 
stained for the lymphatic vessel antigen LYVE-1 (red). In an uninfected 
mouse cornea, lymphatic vessels are found in the limbus but do not ex-
tend into the cornea (marked by dashed line). After HSV-1 infection, lim-
bal lymphatics sprouts and vessels extend into the cornea proper. Images 
are representative of a minimum of three independent experiments with a 
total of n = 12 corneas per time point. Bars, 100 µm.104 HSV-1–induced lymphangiogenesis | Wuest et al.
vessels may have an impact on the adaptive immune response 
to HSV-1, which could theoretically complicate data analysis. 
Thus, corneas were harvested for examination of LYVE-1 ex-
pression at day 5 rather than day 7 PI. Previously described 
either VEGFR-2 or VEGFR-3 fused to the human IgG1 Fc 
domain, labeled VEGFR2-Fc or VEGFR3-Fc, respectively. 
Inhibitors were administered by subconjunctival injection to 
mock- or HSV-1–infected animals. The presence of lymphatic 
Figure 2.  HSV-1–induced lymphangiogenesis is comparable to hemangiogenesis and persists beyond resolution of infection. To compare the 
relative rates of lymphangiogenesis and hemangiogenesis, C57BL/6 mice were infected with 105 PFU HSV-1 and examined for LYVE-1 (red) and CD31 
(green) expression. (A) In uninfected animals, blood (CD31HI) and lymphatic vessels (LYVE-1+) are confined to the limbus (dashed line), but by day 7 PI, 
both vessel types extend into the cornea. Extension of lymphatic vessels is comparable to that of blood vessels. Bars, 500 µm. This panel is representative 
of two experiments with a total of eight corneas. (B) The kinetics of lymphangiogenesis and hemangiogenesis differ with infiltration of LYVE-1+ vessels 
preceding that of CD31HI blood vessels, as shown by semiquantitative analysis of LYVE-1+ and CD31HI expression indicated as percent area of 100× fields 
of view as a function of days PI with 105 PFU HSV-1. The results depicted are a summary of two experiments with eight corneas per time point and four 
independent 100× fields of view quantified per cornea. The results are displayed as mean ± SEM percentage area. *, P < 0.05; **, P < 0.01, comparing in-
fected to uninfected (UI). (C) To determine if dilation of limbal lymphatics could be contributing to increases in LYVE-1+ percent area measurements, cor-
neas were harvested from animals that were either uninfected or at day 5 PI and quantified for LYVE-1 expression. LYVE-1+ area at day 5 PI was 
significantly elevated (**, P < 0.01) compared with the uninfected. The increase in percent area was comparable to that observed in corneas harvested 
with limbal lymphatics (B, day 0 to day 5 PI LYVE-1+ area percentage increase of 2.99 ± 0.7% vs. a LYVE-1+ area percentage increase of 3.3 ± 0.6%), indi-
cating that LYVE-1+ percent increase was not simply the result of limbal lymphatic dilation. (D) To determine if HSV-1–induced lymphatics existed in cor-
neas past the resolution of viral replication, C57BL/6 mice were infected with 103 PFU HSV-1 and followed to day 30 PI. LYVE-1+ percentage area was 
significantly (P < 0.01) elevated relative to uninfected controls. Error bars in C and D represent the SEM based on the results of each cornea sample sum-
marized for both experiments. (E) Both LYVE-1+ lymphatic and CD31HI blood vessels were observed throughout the corneas of latently infected animals. 
Confocal images of representative corneas from animals latently infected with 103 PFU HSV-1 showing LYVE-1+ and CD31+ vessels at day 30 PI. Bar, 500 µm. 
Graphs shown in C and D are a summary of two experiments with four corneas per group per time point of four independent 100× fields of view quanti-
fied per cornea.JEM VOL. 207, January 18, 2010 
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4.8% ± 0.6% in control IgG-treated HSV-1–infected corneas 
to 2.4% ± 0.7% in VEGFR2-Fc–treated HSV-1–infected cor-
neas. The LYVE-1+ percentage area in VEGFR2-Fc–treated 
corneas was not significantly different from that of control 
IgG-treated uninfected eyes (1.79 ± 0.2%; Fig. 3 C). Thus, the 
mechanism of HSV-1–induced lymphangiogenesis was unique 
in its dependence on VEGFR-2 but not VEGFR-3 ligands.
The effective inhibitor of HSV-1–induced lymphangio-
genesis, VEGFR2-Fc, binds VEGF-A/C/D, whereas VEGFR3-
Fc binds VEGF-C/D only, implicating VEGF-A. To test 
models of inflammatory lymphangiogenesis are inhibited by 
blockade of VEGFR-3 ligands (Cursiefen et al., 2003, 2004b; 
Watari et al., 2008; Kataru et al., 2009). However, no inhibi-
tion of HSV-1–induced lymphangiogenesis was observed 
after administration of VEGFR3-Fc (Fig. 3 C), even though 
VEGFR3-Fc significantly inhibited corneal lymphangiogenesis 
in response to placement of a full penetration single suture within 
the cornea (Fig. 3 D). Rather, HSV-1–induced lymphangio-
genesis was completely blocked by VEGFR2-Fc (Fig. 3 C), 
with LYVE-1+ corneal percentage areas being reduced from 
Figure 3.  HSV-1–induced lymphangiogenesis is dependent on VEGF-A/VEGFR-2 but not VEGFR-3 ligands. (A and B) LYVE-1+ (red) vessels ex-
tending into the cornea after HSV-1 infection were positive for VEGFR-2 (A) and VEGFR-3 (B). Isotypic control staining is shown in Fig. S1. LV, lymphatic 
vessel; BV, blood vessel. Data are representative of two experiments. n = 6 per group. The image was acquired with a 400× objective. Bars, 100 µm.  
(C) Mock- or HSV-1–infected animals were treated with competitive inhibitors of VEGF family members, including VEGFR2-Fc or VEGFR3-Fc, which bind 
VEGF-A/C/D or VEGF-C/D, respectively. Lymphatic vessel area was quantified using LYVE-1 and expressed as percent area of 100× fields of view. The in-
hibitor VEGFR2-Fc significantly (**, P < 0.01) inhibited HSV-1–associated lymphangiogenesis, whereas VEGFR3-Fc was ineffective. (D) VEGFR3-Fc was 
capable of inhibiting (**, P < 0.01) lymphangiogenesis through 5 d after the placement of a full penetration suture through the cornea when used with 
the same doses and schedule as with the experiment shown in C. (E and F) To determine if VEGF-A or VEGFR-2 were directly responsible for HSV-1– 
induced lymphangiogenesis, mock- or HSV-1–infected animals were treated with either control IgG or neutralizing antibody against VEGF-A (E) or 
VEGFR-2 (F), both of which significantly (**, P < 0.01; *, P < 0.05) inhibited HSV-1–induced lymphangiogenesis. Error bars in C–F represent the SEM based 
on the results of each cornea sample summarized for both experiments. (G) Representative images of HSV-1–associated lymphatic vessels after subcon-
junctival injections of control rat IgG, anti–VEGF-A, or anti–VEGFR-2, visualized using LYVE-1 (red). Dashed lines show demarcation between the limbus 
and the cornea proper. Bars, 500 µm. Data showing lymphatic vessel area after antibody or VEGFR2/3-Fc treatment is a summary of two experiments with 
12 corneas and four 100× fields of view quantified per cornea.106 HSV-1–induced lymphangiogenesis | Wuest et al.
dependence on VEGF-A and its lymphatic vessel–expressed 
receptor VEGFR-2, monoclonal antibodies against VEGF-A 
and VEGFR-2 were administered. As with VEGFR2-Fc, 
anti–VEGF-A and anti–VEGFR-2 completely blocked HSV-
1–induced increases in LYVE-1+ percentage areas when com-
pared with animals treated with control IgG, which were either 
mock infected or infected with HSV-1 (Fig. 3, E and F). Treat-
ment with anti–VEGF-A and anti–VEGFR-2 reduced vessel 
extension into the cornea (Fig. 3 G), and preexisting limbal 
lymphatics in treated groups largely resembled those observed 
in uninfected animals. Thus, the mechanism of HSV-1–induced 
lymphangiogenesis differs from previously described models in 
that it is not dependent on VEGFR-3 ligands but VEGF-A/
R-2 signaling is required.
Real-time RT-PCR was used to analyze the levels of tran-
scripts for  VEGF-A, C, and D relative to -actin. The  VEGF-A 
transcript  was  rapidly  up-regulated  after  HSV-1  infection, 
with detection as early as day 1 PI and continued expression 
through day 5 PI (Fig. 4 A). In contrast, no up-regulation of 
either  VEGF-C or D transcript was observed through day 5 PI 
(Fig. 4 A). Also in contrast, corneal suture placement induced 
significant up-regulation of VEGF-C by real-time RT-PCR 
(Fig. 4 B). Notably, HSV-1 infection of sutured corneas did 
not result in either down-regulation or additional up-regula-
tion of VEGF-C (Fig. 4 C). Protein levels of VEGF-A in the 
cornea largely mirrored that of VEGF-A transcript with a 
rapid increase in VEGF-A levels by day 1 (Fig. 4 D). By day 3 
PI, VEGF-A levels fell to 32 ± 15 pg/mg but remained ele-
vated above baseline (4.8 ± 0.4 pg/mg of cornea) through   
day 5 PI (Fig. 4 D). Collectively, our results suggest that acute 
HSV-1–induced  lymphangiogenesis  is  strictly  dependent   
on VEGF-A/VEGFR-2, whereas VEGFR-3 ligands do not 
play a role, likely because of the absence of expression during   
HSV-1 infection.
Macrophages do not play a role  
in HSV-1–induced lymphangiogenesis
Previously described models of inflammatory lymphangi-
ogenesis are dependent on macrophage recruitment and 
activation (Cursiefen et al., 2003, 2004b; Watari et al., 2008; 
Kataru  et  al.,  2009). Activated  macrophages  exert  pro-
Figure 4.  VEGF-A expression is up-regulated after HSV-1 infec-
tion. (A) Corneal levels of VEGF-A/C/D were quantified by real-time RT-
PCR and normalized per 1,000 transcripts of the housekeeping gene 
-actin with values given at the indicated day PI. Although HSV-1 infec-
tion induced up-regulation of VEGF-A, no up-regulation of VEGF-C or -D 
was observed. **, P < 0.01, comparing infected to uninfected groups. The 
figure is a summary of two experiments. n = 3 per group per experiment. 
(B) However, at day 5 after corneal suture placement VEGF-C messenger 
RNA was significantly up-regulated relative to both untreated and HSV-
1–infected corneas, here expressed as fold induction using the house-
keeping gene -actin for normalization. **, P < 0.01 comparing the 
suture-induced VEGF-C level to the HSV-1 and uninfected (UI) groups. 
The figure is a summary of two experiments, n = 3 per group per experi-
ment. (C) To determine if HSV-1 infection may suppress VEGF-C expres-
sion, sutured mice were either mock infected or infected with HSV-1 at 
the time of suture placement and the corneas were collected at day 5 
after suture/PI. HSV-1 infection did not affect VEGF-C expression after 
suture placement. A summary of two experiments is shown with a total 
of n = 6 per group. **, P<.01 comparing the uninfected to the other two 
groups. NSD, no significant difference. (D) Protein levels for VEGF-A were 
measured by cytokine bead array after HSV-1 infection, expressed as pi-
cograms of VEGF-A per milligram of wet cornea mass. VEGF-A protein 
expression was rapidly up-regulated and remained up-regulated through-
out the course of the study. **, P < 0.01; *, P < 0.05, comparing levels of 
VEGF-A protein at time points PI to uninfected (day 0 [D0]) control. The 
figure is a summary of two experiments, n = 6 corneas per time point. 
Error bars in A–D represent the SEM based on the results of each cornea 
sample summarized for both experiments.
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Furthermore, although macrophage reduction via admin-
istration of clodronate liposomes significantly reduced the   
absolute numbers of corneal F4/80+CD45HI cells detected via 
flow cytometry (79 ± 23 cells in control-treated versus 25 ± 
8 cells in clodronate liposome-treated eyes; Fig. 5 B), HSV-
1–induced lymphangiogenesis was not affected as determined 
by  measurement  of  LYVE-1+  percentage  area  in  random 
fields of view (Fig. 5 B, 5.5% ± 0.9% vs. 5.1% ± 0.9% in 
PBS-treated vs. clodronate liposome–treated groups, respec-
tively). To determine if bone marrow–derived cells made a 
structural contribution to lymphatic vessels, chimeric mice 
with bone marrow cells expressing GFP under the chicken 
-actin were infected with HSV-1. Despite extensive infil-
tration of GFP+ bone marrow–derived cells into the cornea, 
appreciable colocalization between GFP and LYVE-1 was   
not observed (Fig. 5 D). This indicates that bone marrow–
derived cells do not transdifferentiate to lymphatic endothe-
lial cells after corneal HSV-1 infection. Collectively, evidence   
lymphangiogenic effects by two distinct mechanisms. First, 
activated macrophages express the prolymphangiogenic cyto-
kines VEGF-A/C/D (Cursiefen et al., 2003, 2004b; Watari   
et al., 2008; Kataru et al., 2009). Second, macrophages and/or 
other bone marrow–derived populations are capable of trans-
differentiation to an endothelial cell phenotype, thereby mak-
ing a direct structural contribution to the lymphatic vessel 
wall (Maruyama et al., 2005).
As  HSV-1–induced  lymphangiogenesis  is  dependent  on 
VEGF-A but not VEGF-C/D, we sought to determine if 
macrophages expressed VEGF-A during infection. Transgenic 
mice expressing GFP under the proximal VEGF-A promoter 
(pVEGF-A–GFP) were infected with HSV-1, harvested at days 
1, 3, and 5 PI, and examined for colocalization of GFP with the 
pan-leukocyte marker CD45. Although both CD45 and GFP+ 
cells were present, expression of GFP by CD45+ cells was 
not observed (Fig. 5 A), indicating that leukocytes were not an 
appreciable source of VEGF-A during HSV-1 infection.
Figure 5.  Macrophages are not involved in HSV-1–induced lymphangiogenesis. (A) Mice expressing GFP under the proximal human VEGF-A pro-
moter were infected with HSV-1 and examined for expression of GFP and the pan-leukocyte marker CD45. No colocalization between GFP reporter and 
CD45 was observed, despite the observation of numerous CD45 cells as well as GFP+ cells, indicating that leukocytes, including macrophages, are not an 
appreciable source of VEGF-A during HSV-1 infection. Shown is an image of a cornea at day 5 PI representative of two experiments. n = 6. The images 
were acquired with a 400× objective. Bars, 50 µm. (B) Macrophages were depleted by subconjunctival injection with either clodronate or control PBS con-
taining liposomes. At day 5 PI, corneal F4/80+ macrophages were quantitated by flow cytometry in control and clodronate-treated groups. Clodronate 
treatment significantly reduced the number of corneal F480+ cells (*, P < 0.05). (C) Corneas were examined for expression of the lymphatic vessel antigen 
LYVE-1 and quantified as a measure of lymphatic vessel area. No significant differences in lymphatic vessel area or structure (not depicted) were observed 
between control and clodronate-treated groups. B and C are summaries of two experiments. Error bars represent the SEM based on the results of each 
cornea sample summarized for both experiments. n = 6. (D) Chimeric mice expressing GFP in bone marrow–derived cells were infected with HSV-1.  
Corneas were examined for expression of GFP (green) and LYVE-1 (red) to detect possible structural contributions from bone marrow–derived cells. How-
ever, no appreciable structural contribution was observed. Data are representative of two experiments. n = 8 animals. Bars, 100 µm.108 HSV-1–induced lymphangiogenesis | Wuest et al.
in corneal epithelial cells. However, an occasional HSV-1–
infected stromal cell also expressed GFP VEGF-A reporter 
(Fig. 7 C). VEGF-A reporter expression could be catego-
rized between either GFP HI or LO with differential HSV-1 
antigen expression between the two groups (Fig. 7 B). In 
GFP HI cells, HSV-1 antigen expression was slightly lower 
than that observed in GFP LO cells, and HSV-1 antigen 
staining was primarily perinuclear in these cells. In contrast, 
GFP LO cells typically expressed high levels of HSV-1 anti-
gen, which was diffuse throughout the cytoplasm. At this   
point, the delineation between high and low GFP-expressing   
cells is unclear and may be the result of differential stages 
within the cycle of viral replication. However, both GFP   
HI and LO cells coexpressed HSV-1 antigen and, thus, the 
sole  source  of  observable  reporter  expression  was  HSV-1–
  infected cells. Therefore, the contribution from leukocytes 
or other uninfected cell populations to VEGF-A expression 
appear negligible.
To determine if HSV-1 was also capable of driving VEGF-A 
expression in human corneal epithelial cells, tert-immortalized 
human corneal epithelial (THCE) cells were analyzed by real 
time RT-PCR after infection with 3 MOI HSV-1. To control 
for variable effects of HSV-1 infection on housekeeping gene 
expression, VEGF-A complementary DNA (cDNA) was mea-
sured relative to the three housekeeping genes: -actin, tata 
binding protein, and GAPDH. The geometric mean of fold in-
duction of VEGF-A relative to each housekeeping gene was 
then calculated and taken as the fold induction of the respective 
sample. Significant up-regulation of VEGF-A occurred as early 
as 8 h PI (Fig. 8 A, P < 0.01) and exhibited 37-fold induction 
relative to uninfected cell expression of VEGF-A by 12 h PI 
(Fig. 8 A, P < 0.01).
To control for the possibility that GFP VEGF-A reporter-
expressing cells in pVEGF-A–GFP mice may express VEGF-A   
of the lack of VEGF-A expression by leukocytes after HSV-1   
infection, lack of impact through macrophage reduction   
via clodronate administration, or of a bone marrow–derived 
structural contribution to lymphatic vessels suggest that nei-
ther macrophages nor other leukocyte populations are likely 
to play an appreciable direct and prolymphangiogenic role 
during acute HSV-1–induced lymphangiogenesis.
The predominant source of VEGF-A during HSV-1 infection 
is HSV-1–infected corneal epithelial cells
The lack of a role for macrophages, as well as the observation 
that VEGF-A expression is highest at day 1 PI (Fig. 4, A and B), 
which precedes leukocyte infiltration into the cornea after 
HSV-1 infection (Kim et al., 2004; Biswas et al., 2006), sug-
gests that resident corneal cells may be a source of VEGF-A. 
Corneas were examined for expression of VEGF-A and HSV-1 
antigen at days 1, 3, and 5 PI. Extensive colocalization of 
VEGF-A and HSV-1 antigen was observed. Furthermore, 
detectable VEGF-A was restricted to the vicinity of HSV-1 
lesions (Fig. 6). Although colocalization was observed, there 
were areas which did not appear to overlap. However, most 
VEGF-A isoforms bind extracellular matrix, and VEGF-A 
would also be expected to be bound to VEGFR-positive 
cells. Therefore, localization of VEGF-A does not indicate 
the site of its source. However, the observation that VEGF-A 
concentrations were greatest at sites of HSV-1 lesions was 
consistent with the hypothesis that cell populations in the vi-
cinity of these lesions were the dominant source of VEGF-A 
during acute infection.
To clarify the cell source, pVEGF-A–GFP mice were in-
fected with 105 HSV-1 and expression of GFP and HSV-1 
antigen was examined. GFP reporter expression was local-
ized exclusively to cells coexpressing HSV-1 antigen at day 
1, 3, and 5 PI (Fig. 7 A, day 1 PI) and was primarily observed   
Figure 6.  VEGF-A expression is localized to HSV-1 lesions. To gauge localization of the source of VEGF-A during HSV-1 infection, corneas were 
stained for HSV-1 antigen (red) and VEGF-A or isotypic control (green). VEGF-A staining was localized to sites of HSV-1 lesions. Representative images are 
shown of two experiments. n = 6 mice. Images were acquired with a 200× objective. Bars, 50 µm.JEM VOL. 207, January 18, 2010 
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pVEGF-A–GFP transgenic mice infected with 105 PFU of 
either HSV-1 or VSV. Although HSV-1 induced high level 
reporter expression (Fig. 8 C), we did not observe GFP ex-
pression in VSV antigen-positive cells (Fig. 8 D). Although this 
assessment is not comprehensive, it is intriguing to note that a 
DNA virus (HSV-1) elicits lymphangiogenesis whereas an RNA 
virus (VSV) does not. Whether this relationship holds for other 
DNA and RNA viruses is unknown at this time.
DISCUSSION
Several studies have clarified the regulation of inflammatory 
lymphangiogenesis during wound healing, chronic bacterial 
infection, and Toll-like receptor (TLR) ligand administration. 
before infection as a result of other stimuli, pVEGF-A–GFP 
transgenic mice were treated with inocula of UV-inactivated 
nonreplicating HSV-1 (corresponding to 105 PFU HSV-1 
before UV inactivation). After UV inactivation, plaque assays 
confirmed complete inactivation of virus (unpublished data). 
Infection with UV-inactivated virus still induced expression 
of GFP (Fig. 8 B). However, both GFP and HSV-1 antigen 
expression per cell was lower than that observed after infec-
tion with infectious virus. Importantly, bystander cells did 
not express GFP reporter.
Next, we sought to determine if HSV-1–induced VEGF-A 
expression was reflective of a general response to viral infection 
or HSV-1 selective. We compared the expression of GFP in 
Figure 7.  The dominant source of VEGF-A during HSV-1 infection is virus-infected cells. To determine the source of VEGF-A, pVEGF-GFPs were 
infected with HSV-1. For VEGF-A transcription, we used a reporter mouse line expressing GFP under the proximal VEGF-A promoter. Corneas were har-
vested at days 1, 3, and 5 PI with HSV-1. (A) GFP (green) was visualized using secondary detection along with HSV-1 antigen (red), shown here from a 
cornea at 24 h PI. Reporter expression was observed exclusively in HSV-1 antigen-positive cells. Although cells expressing GFP reporter were positive for 
HSV-1 antigen, in cells expressing the highest levels of GFP, HSV-1 antigen staining was predominantly perinuclear, possibly reflecting a particular stage 
in viral replication. GFP HI cells are highlighted by arrows. Images were acquired with a 400× objective. Data are representative of two experiments. n = 6. 
Bars, 50 µm. (B) High-objective (600×) image of GFP HI and LO expressing HSV-1 antigen-positive cells. Bars, 20 µm. (C) Although the vast majority of 
cells infected with HSV-1 through day 5 PI are corneal epithelial cells, stromal cells expressing HSV-1 antigen also expressed GFP reporter for VEGF-A. 
Bars, 20 µm.110 HSV-1–induced lymphangiogenesis | Wuest et al.
esis  was  dependent  on  VEGF-A  derived  from  HSV-1–
  infected cells.
The basis for a lack of a role for VEGFR-3 ligands is cur-
rently unclear. Regulation of VEGF-C and D expression is 
poorly studied but NF-B activation is crucial to both  VEGF-
C and D expression and is up-regulated during HSV-1 infec-
tion (Chilov et al., 1997; Amici et al., 2001; Taddeo et al., 
2003; Hsieh et al., 2004; Watari et al., 2008). Yet, we did not 
observe up-regulation of VEGF-C or D transcript or of any 
impact from competitive inhibition using VEGFR3-Fc de-
spite abundant expression of VEGFR-3 on HSV-1–induced 
To our knowledge, before this study no attempts had been 
made to clarify the existence or mechanism of inflammatory 
lymphangiogenesis during chronic inflammation as a result of 
viral infection. Inflammatory lymphangiogenesis during wound 
healing and bacterial infection depends on macrophage infil-
tration for subsequent production of the prolymphangiogenic 
cytokines VEGF-C and D (Cursiefen et al., 2003. 2004b; 
Watari et al., 2008; Kataru et al., 2009). However, HSV-1–
induced lymphangiogenesis differed in both the absence of 
the requirement for macrophage recruitment and dependence 
on VEGF-C or D. Rather, HSV-1–elicited lymphangiogen-
Figure 8.  HSV-1 induces VEGF-A up-regulation in THCEs and up-regulation of VEGF-A is HSV-1 specific. (A) THCE cells were infected with  
3 MOI of HSV-1 and then analyzed by real-time RT-PCR for the expression of VEGF-A relative to the housekeeping genes -actin, TBP, and PPIA. The fold 
induction of VEGF-A at each time point was calculated relative to each respective housekeeping gene and then the geometric mean was taken as the fold 
induction of VEGF-A per sample. Data are a summary of two experiments, with a total of n = 6 per time point. Data are expressed as mean ± SEM fold 
induction. **, P < 0.01, comparing infected to uninfected cells. (B) pVEGF-A–GFP transgenic mice were infected with a dose of replication incapable UV-
inactivated HSV-1 corresponding to 105 PFU HSV-1 before inactivation. At 24 h PI, corneas were harvested and examined for localization of GFP relative 
to HSV-1 antigen. Cells expressing GFP costained for HSV-1 antigen expression, whereas neighboring bystander cells did not. Data are representative of 
two experiments with a total of n = 6. Bars, 20 µm. (C and D) Although HSV-1 induced up-regulation of GFP in pVEGF-A–GFP mice (C), infection with VSV 
did not (D), indicating that the up-regulation of VEGF-A after HSV-1 infection may be the result of an HSV-1–specific pathway. Bars, 50 µm. Data are 
representative of two experiments with a total of n = 6.JEM VOL. 207, January 18, 2010 
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ing lymph nodes, which are required for the induction of 
graft rejection (Yamagami and Dana, 2001).
An  earlier  study  of  HSK-associated  hemangiogenesis 
demonstrated that during corneal HSV-1 infection, VEGF-A 
was predominantly localized to the corneal epithelium at sites 
of HSV-1 lesions (Biswas et al., 2006), which is consistent 
with our observations. However, this study asserted that unin-
fected corneal epithelial cells in close proximity to HSV-1–
infected cells were the predominant source of VEGF-A. This 
conclusion was based on the observation that VEGF-A+ cells 
were localized immediately neighboring on cells expressing a 
GFP reporter under the promoter for HSV-1 glycoprotein C 
(gC). However, gC is a true late gene and gC transcription 
does not commence until the completion of viral DNA syn-
thesis (Yamamoto et al., 2006). Thus, a lag time exists after   
viral  infection  before  detection  of  reporter  expression   
(Zabierowski and DeLuca, 2004). Should  VEGF-A expression   
occur in HSV-1–infected cells before gC expression, the use 
of this reporter to detect infected cells would lead to the er-
roneous conclusion that uninfected cells were the primary 
source of VEGF-A. In addition, most VEGF-A isoforms con-
tain  extracellular  matrix  binding  domains.  Localization  of 
VEGF-A  is  not  restricted  to  sites  of VEGF-A  expression 
(Yamazaki and Morita, 2006), and a concentration gradient 
from sources to VEGFR is required for exertion of proangio-
genic or prolymphangiogenic effects (Yamazaki and Morita, 
2006). To avoid these issues we used reporter mice expressing 
GFP  under  the  proximal VEGF-A  promoter  to  identify 
VEGF-A–expressing  cells  as  well  as  polyclonal  antibody 
against whole HSV-1 to identify HSV-1–infected cells. In-
fected primarily corneal epithelial cells at time points assayed 
were the sole detectable source of GFP reporter.
Studies to address the mechanism of VEGF-A up-regula-
tion are ongoing. Theoretically, HSV-1–associated TLR ligands 
acting through either MyD88 or TRIFF adaptor proteins may 
participate, as activation of MyD88 by several different TLR 
ligands up-regulates VEGF-A expression (Pinhal-Enfield et al., 
2003; Varoga et al., 2006; Macedo et al., 2007; Koff et al., 
2008). MyD88 deficiency also reduces VEGF-A levels during 
the early course (day 2 PI) of corneal HSV-1 infection (Sarangi 
et al., 2007). Although no significant difference in VEGF-A 
levels between WT and MyD88-deficient animals is found by 
day 4 PI (Sarangi et al., 2007), a time point at which VEGF-A 
production is still dominated by HSV-1–infected cells, interpre-
tation may be complicated by elevated viral replication in 
MyD88-deficient animals that may up-regulate VEGF-A 
through otherwise less dominant compensatory pathways. A 
role for TRIFF-dependent TLR signaling would appear less 
likely. Even though the TRIFF-dependent TLR, TLR3, is be-
lieved to be the primary TLR involved in recognition of HSV-1 
infection (Zhang et al., 2007), activation of TRIFF via TLR3 
ligands inhibits VEGF-A expression (Kleinman et al., 2008). 
However, inhibition of VEGF-A expression by TRIFF activa-
tion requires downstream expression of IFN- (Kleinman et al., 
2008). HSV-1 ICP0 inhibits signaling downstream of IFN- 
(Härle et al., 2002b), possibly alleviating VEGF-A repression.
lymphatic vessels. The primary sources of VEGFR-3 ligands 
during inflammation are infiltrating macrophages (Cursiefen 
et al., 2003, 2004b; Kerjaschki, 2005; Cursiefen, 2007; Watari 
et al., 2008; Kataru et al., 2009). During HSV-1 infection, 
macrophage infiltration is extensive. However, these cells were 
irrelevant to HSV-1–induced lymphangiogenesis, suggesting 
that the function and activity of macrophages differed be-
tween macrophages infiltrating the cornea during HSV-1 in-
fection as opposed to wound healing or other sources of 
inflammation (Kubota et al., 2009). Hypoxia functions to re-
press VEGF-C production while elevating VEGF-A expres-
sion (Gunningham et al., 2001). But the possibility of hypoxic 
corneal conditions alone do not provide a satisfactory expla-
nation, as hypoxia induces macrophage production of VEGF-
A (Ray et al., 2009), yet no VEGF-A reporter expression by 
CD45+ cells was observed during HSV-1 infection. We also 
did not observe a suppressive effect of HSV-1 infection on 
VEGF-C  up-regulation  after  suture  placement  (Fig.  4  C). 
Thus, it appears that the lack of VEGF-C up-regulation by 
HSV-1 infection is a result of the absence of   VEGF-C–induc-
ing signaling pathways activated during other forms of in-
flammation  rather  than  a  VEGF-C–suppressive  pathway 
activated by HSV-1 infection.
VEGF-A/VEGFR-2–induced lymphatic vessels differ in 
structure and function from those induced by VEGFR-3 li-
gands, exhibiting a relatively dilated, leaky, and poorly func-
tional phenotype (Nagy et al., 2002; Hong et al., 2004b; Kajiya 
et al., 2006). HSV-1–elicited lymphatic vessels are likely to be 
poor transporters of antigen compared with vessels induced 
by VEGF-C or D. However, they are still capable of draining 
soluble antigen from the cornea to the lymph nodes. FITC-
labeled high molecular mass dextran injected intrastromally 
into the cornea of HSV-1–infected mice is rapidly transported 
through lymphatic vessels to draining lymph nodes (Figs. S2). 
HSV-1–induced lymphatic vessels remained intact and func-
tional well beyond resolution of infection. The normal hu-
man cornea is immunologically privileged, but during HSK, 
chronic inflammation mediated by the host immune response 
results in blinding corneal opacity (Carr et al., 2001; Biswas et 
al., 2006). Part of the basis for corneal immunological privi-
lege is the absence of lymphatic vessels (Niederkorn, 2003; 
Streilein, 2003; Cursiefen, 2007). The lack of presentation of 
eye antigens during normal development prevents the induc-
tion of T cell anergy (Lambe et al., 2007). Lymphangiogenesis 
during ocular HSV-1 infection may be a driving force behind 
the loss of immunological privilege by allowing the transport 
of corneal antigens. Studies assessing the impact of corneal 
lymphatics on antigen presentation and immunological privi-
lege are ongoing. Lymphangiogenesis may also negatively af-
fect standard treatment for HSK. In severe cases, patients may 
require corneal transplant to restore vision. However, corneal 
transplant rejection rates in patients with HSK are unusually 
high (Larkin, 1998). The presence of corneal lymphatic vessels 
is associated with an elevated risk of graft rejection (Larkin, 
1998; Cursiefen et al., 2003, 2004a; Regenfuss et al., 2008) 
that is likely the result of enhanced antigen transport to drain-112 HSV-1–induced lymphangiogenesis | Wuest et al.
MATERIALS AND METHODS
Immunofluorescence microscopy and quantitative analysis of lym-
phangiogenesis. Corneas were prepared and stained for specific antigens as 
described previously (Wuest et al., 2006a). LYVE-1 expression was quanti-
tated by taking 100× objective images of corneas with the top of the field 
localized to include lymphatic vessels in the limbus of the eye as well as any 
lymphatic vessels extending into the cornea. The cornea was oriented such 
that the corneal area included was equivalent between individual corneas by 
using limbal lymphatics and the delineation between the cornea and limbus 
as reference points. Images were analyzed with MetaMorph Imaging Suite 
v7.0 (MDS Analytical Technologies), with the lymphatic vessel area defined 
as the percentage of LYVE-1+ pixels divided by the total number of pixels 
per field of view. The sources of antibodies used are the following: rabbit 
anti–HSV-1, rat anti–mouse CD45, goat anti–mouse VEGFR-2, rabbit anti–
mouse LYVE-1 (Abcam), goat anti-GFP, FITC rat anti–mouse CD31 (AbD 
Serotec), Alexa Fluor 546 goat anti–rabbit, Alexa Fluor 568 rabbit anti–goat, 
Alexa Fluor 647 chicken anti–rabbit, (Invitrogen), goat anti–mouse VEGF-A 
(R&D  Systems),  FITC  rat  anti–mouse  F4/80  (BD),  goat  anti–mouse   
VEGFR-3  (Thermo  FIsher  Scientific),  DyLight  549  donkey  anti–rabbit,   
DyLight 549 anti–rat, and FITC bovine anti–goat (Jackson ImmunoResearch 
Laboratories). Images were taken using an epifluorescence/confocal laser-
scanning microscope (IX81-FV500; Olympus).
Flow cytometry and cytokine measurement. Corneas and lymph nodes 
were processed for flow cytometry and quantitation of the absolute number 
of macrophages or FITC-Dextran–labeled cells was performed as previously 
described (Wuest et al., 2006b; Wuest and Carr, 2008). FITC-Dextran levels 
in the draining lymph nodes was assessed in terms of arbitrary units using the 
multiple of total FITC-Dextran+ events times their mean fluorescence in-
tensity. VEGF-A levels were measured by cytokine bead array using a Bio-
plex suspension array system (Bio-Rad Laboratories) as previously described 
(Wuest and Carr, 2008).
Macrophage depletion and inhibition of lymphangiogenesis. PBS- 
and clodronate-containing liposomes were the gift of N. van Rooijen (Vrije 
Universiteit  Medical  Center,  Amsterdam,  Netherlands).  Corneal  macro-
phages were depleted using clodronate liposomes. Mice were given subcon-
junctival  injections  of  10  µL  of  either  clodronate-  or  PBS-containing 
liposomes at days 3, 0, 2, or 4 relative to the time of infection. Corneas 
were harvested at day 5 PI and the number of F4/80+ cells was determined 
as well as lymphatic vessel area. To competitively inhibit the prolymphangi-
ogenic VEGF family members VEGF-A, C, or D, mice were injected sub-
conjunctivally with 10 µl of recombinant human IgG1, VEGFR2-Fc, or 
VEGFR3-Fc (R&D Systems), all at a concentration of 100 µg/ml in sterile 
0.1% BSA in PBS. The injections were performed at time points of days 0, 
2, and 4 relative to the time of infection with HSV-1. For experiments using 
antibody neutralization of VEGF-A and VEGFR-2, monoclonal rat anti–
mouse VEGFR-2 (clone AP-MAB-0701; Angio-Proteomie), monoclonal 
rat anti–mouse VEGF-A (clone 2G11-2A05; BioLegend), or purified rat 
IgG (Angio-Proteomie) were administered by 10-µl subconjunctival injec-
tions at days 0, 2, and 4, all at a concentration of 100 µg/ml in sterile 0.1% 
BSA in PBS. Corneas were harvested at day 5 PI and lymphatic vessel area 
was determined. For study of VEGFR-3–dependent lymphangiogenesis in 
response to corneal suture placement, a single number 7 braided silk suture 
was placed in the center of the cornea of C57BL/6 mice. Suture versus non-
sutured animals received either control IgG or VEGFR3-Fc using the same 
doses and dosing schedule as with experiments using HSV-1.
Dye  transport  assays.  FITC-labeled  dextran  (2,000  kD  lysine  fixable 
FITC-Dextran) was injected into the cornea intrastromally via glass needle 
in a volume of 1 µl at a concentration of 10 mg/ml in PBS, using a gas-powered   
microinjection system (MDI) under an ophthalmic surgical microscope   
(Carl Zeiss , Inc.) at days 0 or 5 PI with HSV-1. Whole eye was harvested at 
1 h after injection and fixed in 4% paraformaldehyde in PBS for 1 h. Lymph 
nodes were fixed for 30 min in 4% paraformaldehyde, soaked in 30% sucrose 
Alternatively, VEGF-A up-regulation may be TLR inde-
pendent. The VEGF-A promoter is well characterized, and 
HSV-1 infection modulates the activity/abundance of three 
transcription factors involved in transcriptional regulation of 
VEGF-A: STAT3, Sp1, and EGR-1 (Imbalzano et al., 1991; 
Kim and DeLuca, 2002, Rajcáni et al., 2004; Pagès and Pouys-
ségur, 2005; Biswas et al., 2006; Iwahori et al., 2007; Chen   
et al., 2008). The impact of STAT3 may be indirect through 
paracrine  activation  by  IL-6  produced  in  HSV-1–infected 
cells (Biswas et al., 2006). However, Sp1 and EGR-1 both ex-
hibit early changes in abundance and activity after infection 
(Imbalzano et al., 1991; Kim and DeLuca, 2002, Rajcáni et al., 
2004; Pagès and Pouysségur, 2005; Iwahori et al., 2007; Chen 
et al., 2008).
VEGF-A antagonists are already in use for the treatment 
of various malignancies and other disease processes. Our re-
sults suggest the possibility for the extension of their utility to 
the management of HSK. We have observed up-regulated ex-
pression of VEGF-A by HSV-1–infected skin epithelial cells 
(unpublished data). Identification of HSV-1–infected cells as 
a source of VEGF-A leads to more questions regarding the 
impact of this cytokine on other facets of HSV-1 disease. DC 
maturation is inhibited during HSV-1 infection (Salio et al., 
1999) and VEGF-A inhibits DC maturation and function via 
VEGFR1 signaling (Soker et al., 1998; Dikov et al., 2005; 
Fricke et al., 2007). VEGF-A also has profound affects on 
neuronal and blood vascular systems that may be clinically 
relevant.  Neuronal  axons  are  guided  to VEGF-A  sources 
through VEGF-A interaction with neuropilins and VEGFRs 
(Neufeld et al., 2002; Schwarz et al., 2004; Yu et al., 2008). 
Sensory neurons feeding the site of primary HSV-1 infection 
are the ultimate target of the virus, as sensory neuron infec-
tion is required for the virus to establish latency within the 
trigeminal ganglia (Taylor et al., 2002). Thus, VEGF-A block-
ade may have profound effects on the course of HSV-1 dis-
ease,  impacting  both  the  initial  course  of  disease  and 
immunological responses to it. It remains to be seen whether 
HSV-1 infection up-regulates the expression of the VEGFR-
1 binding  VEGF family members  VEGF-B and PlGF. Delayed 
up-regulation of expression of either of these cytokines could 
provide an explanation for the disparate time course between 
lymph and hemangiogenesis during HSV-1. Although blood 
vessels express VEGFR-1, which signals synergistically with 
VEGFR-2 (Fischer et al., 2007), lymphatic vessels do not ex-
press VEGFR-1 (Hong et al., 2004a).
In summary, this paper is the first in vivo study that addresses 
inflammatory lymphangiogenesis during viral infection. In con-
trast to established models of inflammatory lymphangiogenesis, 
HSV-1–induced lymphangiogenesis was not dependent on the 
VEGFR-3 ligands VEGF-C and D or on macrophage infiltra-
tion. Instead, lymphangiogenesis was dependent on VEGF-A, 
and VEGF-A production by HSV-1–infected cells was not a 
general response to viral infection, as VSV–infected cells did not 
cause VEGF-A expression. Lymphatic vessels persisted well past 
resolution of infection and may contribute to chronic inflamma-
tion and blindness in susceptible patients.JEM VOL. 207, January 18, 2010 
Article
113
son tests. All statistical analysis was performed with GBSTAT (Dynamic 
Micro Systems).
Online supplemental material. Fig. S1 shows isotypic control antibody 
for anti-VEGFR2 and anti-VEGFR3 staining shown in Fig. 3. Fig. S2 shows 
corneal lymphatic vessel transport of soluble antigen in infected and unin-
fected mice. Online supplemental material is available at http://www.jem 
.org/cgi/content/full/jem.20091385/DC1.
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